Renovaro BioSciences, formerly known as Enochian BioSciences Inc., is an advanced biotechnology firm that specializes in cell, gene, and immunotherapy. The company’s primary goal is to achieve long-term or life-long remission in some of the deadliest cancers while also treating or curing serious infectious diseases. Their oncology platform is currently focused on pancreatic cancer, but they plan to expand their studies to include other solid tumors with short life expectancies.
Renovaro utilizes proprietary and novel technology that uses cell and gene therapy to stimulate an enhanced immune response against solid tumors. The effectiveness of this approach has been confirmed through studies conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA. These studies demonstrated a significant reduction in pancreatic tumor size and weight, ranging from 80% to 90%, along with a marked improvement in key aspects of the immune response.
The positive results from these studies have formed the basis for a pre-IND submission to the U.S. Food and Drug Administration. Renovaro’s first in human phase I/IIa studies are on track to begin by mid-2024. These studies will further investigate the potential of their dendritic cell-based therapy on various solid tumors.
Renovaro BioSciences is dedicated to advancing the field of cancer treatment and infectious disease therapy through innovative cell, gene, and immunotherapy approaches. Their efforts have the potential to revolutionize treatment options and provide hope for patients with limited life expectancies due to cancer or serious infections.
Sources:
– Renovaro BioSciences Inc. website: https://enochianbio.com
– InvestorBrandNetwork website: https://ibn.fm/RENB
